🔎 Trials Near Me

Почетна › Множен миелом › Џорџија › Atlanta

Клинички испитувања за Множен миелом во Atlanta, GA

Една студија за Множен миелом бара учесници на локација во или блиску до Atlanta. Отворете ја за да видите кој може да учествува и како да го контактирате тимот.

Официјален текст на студијата (англиски)

Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Се регрутираФаза 3
  • Research Site, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07391657

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Се регрутираФаза 1/2
  • Emory University Winship Cancer Center, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT04973605

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 3
  • Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Се регрутираФаза 1
  • Research Site, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07073547

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

Се регрутираФаза 1
  • Winship Cancer Institute Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06768489

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 3
  • Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07258511

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 2
  • Emory University Winship Cancer Institute, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT04634552

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Се регрутираФаза 3
  • Emory University - Winship Cancer Institute, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07393282

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Се регрутираФаза 4
  • Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05201781

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 1/2
  • Emory University Hospital, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07116616

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Се регрутираФаза 2/3
  • Winship Cancer Institute of Emory University /ID# 277667, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07095452

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Се регрутираФаза 2
  • Cancer Treatment Centers of America - Atlanta, Atlanta
  • Emory University Winship Cancer Institute, Atlanta
Возраст 12 и постари · Сите полови · Ажурирано 22.9.2026 · NCT02693535

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Се регрутираФаза 1/2
  • Winship Cancer Institute of Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT04879043

Collection of Tissue Samples for Cancer Research

Се регрутираНабљудувачка студија
  • Emory University, Atlanta
2 Months · Сите полови · Ажурирано 16.9.2026 · NCT00900198

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Се регрутираФаза 3
  • Winship Cancer Institute, Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT06615479

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 2
  • Winship Cancer Institute of Emory University, Atlanta
  • Northside Hospital, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06297226

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Се регрутираФаза 3
  • Emory University Hospital Midtown, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT07555938

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Се регрутираФаза 2
  • Emory University/Winship Cancer Institute, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT05208307

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Се регрутираФаза 1
  • Emory University Hospital, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT07075185

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 1/2
  • Research Site, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 27.8.2026 · NCT07681596

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Се регрутираФаза 1/2
  • Research Site, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT06106945

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Се регрутираФаза 1
  • The Winship Cancer Institute of Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Се регрутираФаза 1/2
  • Research Site, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Се регрутираФаза 3
  • Research Site, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 14.8.2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Се регрутираФаза 1
  • Winship Cancer Institute, Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 12.8.2026 · NCT07280013

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Се регрутираФаза 2
  • Winship Cancer Institute, Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 6.8.2026 · NCT07284758

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Се регрутираФаза 4
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 23.7.2026 · NCT07101445

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Се регрутираФаза 1/2
  • Winship Cancer Institute of Emory University /ID# 274830, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 21.7.2026 · NCT06892522

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Се регрутираФаза 1
  • Northside Hospital, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 16.7.2026 · NCT06121843

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Се регрутираФаза 1
  • Winship Cancer Institute of Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 8.7.2026 · NCT05137054

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Се регрутираФаза 1/2
  • Emory Winship Cancer Institute, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 24.6.2026 · NCT04068597

Personalized Autologous Transplant for Multiple Myeloma

Се регрутираФаза 1
  • Winship Cancer Institute of Emory University, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 15.6.2026 · NCT04483206

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Се регрутира
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 5.6.2026 · NCT03858205

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Се регрутираФаза 3
  • Emory University Hospital, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 4.6.2026 · NCT05243797

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Се регрутираФаза 1
  • Emory Winchip Cancer Center, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 19.5.2026 · NCT06433947

CAR T-cell Therapy in Patients With Renal Dysfunction

Се регрутираФаза 2
  • Caitlin Guzowski, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 20.4.2026 · NCT05909059

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 1/2
  • Emory University Hospital, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 20.4.2026 · NCT03761108

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Се регрутираФаза 1
  • Winship Cancer Institute, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 1.4.2026 · NCT05862012

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Се регрутираФаза 1/2
  • Emory University Hospital, Atlanta
Возраст 18 и постари · Сите полови · Ажурирано 3.6.2025 · NCT06119685

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Се регрутираФаза 1
  • Northside Hospital, Atlanta
Возраст од 18 до 75 · Сите полови · Ажурирано 2.8.2024 · NCT06271252

Испитувања за Множен миелом во други градови

Други студии во Atlanta

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.